Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of ATH-063 in Healthy Subjects
NCT05807971Phase 1Completed
- Sponsor
- Athos Therapeutics
- Start
- Apr 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ATH-063 in inflammatory bowel disease (IBD), Crohn's disease and ulcerative colitis (UC) (5 arms), sponsored by Athos Therapeutics. Primary endpoint: Safety and Tolerability up to 24 days. Started Apr 2023; status: completed.
02
Drugs
ATH-063
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05807971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05807971.